04 Aug 2008 · Tracleer® (bosentan) receives EU approval for treatment of patients with mildly symptomatic Pulmonary Arterial Hypertension

22 Jul 2008 · Actelion announces Half Year financial results 2008

Total net revenues of CHF 676.0 million - Product sales up 18 percent in local currencies compared to H1 2007 - Tracleer® sales of CHF 605.2 million - Cash EBIT of CHF 190.8 million - Multiple Phase III studies on track - Substantial impact from Actelion/GSK orexin receptor antagonist collaboration to start immediately in H2 2008

14 Jul 2008 · Actelion and GlaxoSmithKline enter into exclusive collaboration to realise the full potential of almorexant in sleep disorders and beyond

Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists

08 Jul 2008 · Actelion to join the SMI (Swiss Market Index)

27 Jun 2008 · Bosentan (Tracleer®) receives positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension

ALLSCHWIL, SWITZERLAND - 27 June 2008 - Actelion Ltd (SWX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for bosentan (Tracleer®) to extend its use in Pulmonary Arterial Hypertension (PAH).

20 Jun 2008 · Pivotal pulmonary arterial hypertension study published in The Lancet concludes that bosentan (Tracleer®) demonstrates benefits in patients with mildly symptomatic WHO Functional Class II disease

ALLSCHWIL, SWITZERLAND - 20 June 2008 - Actelion Ltd (SWX: ATLN) announced today that data published in The Lancet[1] show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Tracleer®) prevented clinical deterioration by significantly delaying time to clinical worsening and reduced the number of patients worsening to WHO FC III/IV. A significant reduction in pulmonary vascular resistance and a positive trend in increasing the 6MWD were also observed. The randomized, placebo-controlled EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) trial is the first and only trial conducted exclusively in a dedicated FC II PAH patient population.

22 Apr 2008 · Actelion announces first quarter 2008 financial results

Total net revenues of CHF 321.6 million - Product sales up 19 percent in local currencies compared to Q1 2007 - Tracleer® sales of CHF 287.6 million with ongoing quarterly buying pattern variations - Cash- EBIT of CHF 99.8 million - Discontinuation of tezosentan development - Four different Phase III programs on track - Partnering discussions with almorexant on schedule

21 Apr 2008 · Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound

11 Apr 2008 · Annual General Meeting of Shareholders in Basel, Switzerland

ALLSCHWIL/BASEL, SWITZERLAND - 11 April 2008 - At today's Annual General Meeting of Actelion Ltd (SWX: ATLN), shareholders approved all resolutions.

29 Feb 2008 · Actelion and Nippon Shinyaku to collaborate on novel PAH compound

ALLSCHWIL/BASEL, SWITZERLAND and KYOTO - 29 February 2008 - Actelion Ltd (SWX: ATLN) and Nippon Shinyaku (TYO: 4516) announced today the two companies have signed a binding letter of intent regarding Nippon Shinyaku's novel PGI-2 receptor agonist NS-304.